Ufi 5mg Tablet contains the active ingredient Solifenacin Succinate. Solifenacin is classified as an antimuscarinic agent and is prescribed to treat overactive bladder (OAB) symptoms.
Ufi 5mg Tablet is primarily prescribed for the treatment of overactive bladder, a condition characterized by symptoms such as urinary urgency, frequency, and incontinence. Solifenacin works by blocking specific receptors (muscarinic receptors) in the bladder, reducing involuntary contractions and promoting better control over bladder function.
Common side effects may include dry mouth, constipation, blurred vision, and urinary retention. It is important to report any unusual or severe side effects to your healthcare provider.
Inform your healthcare provider about any pre-existing medical conditions, especially glaucoma, liver or kidney disorders, or urinary retention.
Disclose all medications, including prescription and over-the-counter drugs, as well as any herbal supplements, to avoid potential interactions.
Be cautious when engaging in activities that require mental alertness, as Solifenacin may cause drowsiness or blurred vision.
When Not to Use:
Ufi 5mg Tablet may not be suitable for use in the following situations:
Known hypersensitivity or allergy to Solifenacin or any components of the tablet.
Urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma.